For life-science researchers, Flagship is the only independent tissue analysis and pathology service provider spanning the entire histopathology process.
Over 100 biotech, pharmaceutical, and medical device firms rely on Flagship’s tissue analysis to determine the safety and effectiveness of emerging therapies. In clinical trials, tissue analysis serves to determine proper doses and evaluate efficacy and toxicity. With emerging personalized medicines, tissue analysis plays a crucial role in determining which people will respond to a new therapy. Flagship is pioneering digital technologies that are accelerating and refining the entire pathology process so that no matter what stage our customers are at in their research, we improve chances of success with reliable quantitative tissue data.
Flagship recognizes the need for customized tissue image analysis solutions developed in tandem by engineers and biologists and pathologists and has built a team of multidisciplinary experts to do just that. With collective experience covering decades in the pharmaceutical, device, and diagnostic industries, our team of pathologists, biologists, histologists, analysts, and regulatory support staff transform tissue samples into sophisticated data and actionable insights.
To ensure the quality our customers need when measuring tissue, our team has developed a complete pathology service including tissue sourcing, histology, custom image analysis, biostatistics, and pathology reports. Projects range from early stage, exploratory, and tissue microarray studies through large, late stage, CLIA-based clinical trials or IDE image analysis companion diagnostics filings. Flagship is platform agnostic on both image analysis and in immunohistochemistry or immunofluorescence, bringing the best solution to the particular client’s tissue challenge. Careful regulatory oversight and quality control have made Flagship a fast-growing leader in the delivery of pharmacodynamics endpoints, biomarker interpretation, and patient selection studies. We have the personnel and processes to scale projects from early small studies through diagnostic assay development and clinical trial evaluations.